This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Expanded Access Program for Epcoritamab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT05733650
Expanded Access Status : Approved for marketing
First Posted : February 17, 2023
Last Update Posted : May 25, 2023
Information provided by (Responsible Party):

Brief Summary:

The purpose of this program is to provide investigational epcoritamab, an antibody also known as GEN3013 (DuoBody-CD3xCD20), in an expanded access setting for eligible patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) who have a high unmet medical need with no other treatment options. It is a requirement that patients do not qualify for an ongoing epcoritamab clinical program or are unable to participate due to logistical reasons.

Access to investigational epcoritamab can be requested by contacting

Condition or disease Intervention/treatment
Large B-cell Lymphoma Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Primary Mediastinal Large B-cell Lymphoma (PMBCL) High Grade B-cell Lymphoma (HGBCL) Grade 3B Follicular Lymphoma Biological: Epcoritamab

Detailed Description:
This is a multicenter program conducted within the United States. The program will consist of screening, treatment (Cycle 1 Day 1 until epcoritamab discontinuation), safety follow-up, post-treatment and/or survival follow-up.

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Treatment IND/Protocol
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Expanded Access Program (EAP) to Provide Epcoritamab (GEN3013) to Eligible Patients With Relapsed or Refractory Large B-cell Lymphoma

Intervention Details:
  • Biological: Epcoritamab
    Eligible patients will receive epcoritamab (28-day cycle) that will be administered as subcutaneous (SC) injections until disease progression, or one or more of the treatment discontinuation criteria are met.
    Other Names:
    • GEN3013
    • DuoBody®-CD3xCD20

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Must be 18 years of age or older
  • R/R CD20+ mature B-cell neoplasm
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0, 1, or 2
  • ≥ 2 prior lines of antineoplastic therapy, including ≥ 1 anti-CD20 monoclonal antibody (mAb)
  • Fluorodeoxyglucose (FDG) positron emission tomography (PET)-avid and measurable disease by computed tomography/magnetic resonance imaging (CT/MRI)
  • Patients considering the EAP should have no other available therapeutic option and cannot be eligible for other epcoritamab trials.
  • Patients considering the EAP must be located in proximity to a US site given that the EAP is currently available only in the United States.
  • Prior to initiating any program-related assessments or procedures, patients (or their legally acceptable representative) must sign an informed consent form (ICF), which indicates the purpose of the program, the procedures required for the program, and confirms the patient's willingness to participate in the program.

Exclusion Criteria:

  • Any prior therapy with an investigational bispecific antibody targeting CD3 and CD20
  • Prior treatment with CAR-T therapy within 100 days prior to first epcoritamab administration
  • Primary central nervous system (CNS) lymphoma or known CNS involvement by lymphoma
  • Confirmed history of or current autoimmune disease or other diseases resulting in permanent immunosuppression or requiring permanent immunosuppressive therapy. Low-dose prednisolone for rheumatoid arthritis or similar conditions is allowed.
  • Active hepatitis B or hepatitis C
  • Known clinically significant cardiac disease
  • Pregnancy or breastfeeding
  • Known hypersensitivity to allopurinol or rasburicase

No Contacts or Locations Provided
Layout table for additonal information
Responsible Party: Genmab Identifier: NCT05733650    
Other Study ID Numbers: GCT3013-101
First Posted: February 17, 2023    Key Record Dates
Last Update Posted: May 25, 2023
Last Verified: May 2023
Keywords provided by Genmab:
Diffuse large B-cell lymphoma
Bispecific antibody
Early access
Double-hit DLBCL
Triple-hit DLBCL
Follicular grade 3b
Transformed DLBCL
High-grade B-cell lymphoma
Primary mediastinal large B-cell lymphoma (PMBCL)
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin